Comparative Pharmacology
Head-to-head clinical analysis: FOAMICON versus METI DERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOAMICON versus METI DERM.
FOAMICON vs METI-DERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOAMICON is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
METI-DERM contains methylprednisolone aceponate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines, phospholipase A2, and prostaglandin synthesis, thereby reducing inflammation, pruritus, and vasodilation.
Adults: 200 mg orally once daily, with or without food.
Apply a thin film topically to affected area once or twice daily.
None Documented
None Documented
Terminal elimination half-life 12-15 hours; clinically, steady-state achieved in ~3 days.
Terminal elimination half-life: 6–8 hours in healthy adults; prolonged to 12–15 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (65% unchanged, 15% as inactive metabolites); biliary/fecal 20%.
Renal: ~60% as unchanged drug and metabolites; biliary/fecal: ~35% as metabolites and unchanged drug; minor respiratory elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid